Blueprint Medicines Data Presented at 62nd ASH Annual Meeting and Exposition Highlight Broad Commitment to Advance Patient Care in Systemic Mastocytosis
"The medical needs in systemic mastocytosis are significant and urgent, and our presentations at the ASH annual meeting demonstrate our efforts to help address these challenges in collaboration with disease experts and the patient community," said
Pure Pathologic Response (PPR) Measures Reduction and Elimination of Mast Cell Burden in Advanced SM, and Significantly Correlates with Improved Overall Survival (OS)
The IWG-MRT-ECNM response criteria (IWG criteria) are the current clinical and regulatory standard for evaluating treatment response in patients with advanced SM, and are primarily based on the resolution of organ damage. With the development of a potent and selective KIT D816V inhibitor, new PPR criteria were established by global SM experts in collaboration with
In the Phase 1 EXPLORER trial, 53 patients with advanced SM were treated with AYVAKIT and evaluable for response per modified IWG criteria as of a data cutoff of
"For patients with advanced systemic mastocytosis, our primary treatment goals are to rapidly reduce their mast cell burden, improve quality of life, and importantly, prolong survival," said
Highly Sensitive Blood-Based Droplet Digital Polymerase Chain Reaction (ddPCR) Test Detects KIT D816V Mutation in 95% of Patients
Registry data have shown a median delay of nine years from symptom onset to diagnosis in patients with non-advanced SM,1 highlighting the need for new diagnostic tools.
In Part 1 of the PIONEER trial of AYVAKIT in patients with non-advanced SM, the sensitivity of ddPCR and next-generation sequencing (NGS) KIT D816V testing was evaluated. As of a data cutoff of
SM Patients Reported Worse Physical Functioning and Mental Health Compared to Historical Data for Patients with Lung and Colorectal Cancer
SM is characterized by unpredictable, severe and life-threatening complications despite best supportive care. To better understand the burden of disease,
The TouchStone survey showed that SM symptoms have a profound impact on patients' daily functioning, mental health, and ability to work or perform usual activities. Compared to prior research on colorectal and lung cancer patients, participants reported worse physical functioning and mental health based on the 12-item
Healthcare providers broadly recognized the high disease burden in SM. A majority reported that non-advanced SM patients under their care feel depressed or discouraged, and limit their activities due to pain or discomfort. For healthcare providers, the most important treatment goals for advanced and non-advanced SM are improved progression-free survival and OS, and better quality of life.
SM is a rare disease driven by the KIT D816V mutation. Uncontrolled proliferation and activation of mast cells result in chronic, severe and often unpredictable symptoms for patients across the spectrum of SM. The vast majority of those affected have non-advanced (indolent or smoldering) SM, with debilitating symptoms that lead to a profound, negative impact on quality of life. A minority of patients have advanced SM, which encompasses a group of high-risk SM subtypes including aggressive SM, SM with an associated hematologic neoplasm and mast cell leukemia. In addition to mast cell activation symptoms, advanced SM is associated with organ damage due to mast cell infiltration and poor OS.
Debilitating symptoms associated with SM, including anaphylaxis, maculopapular rash, pruritis, brain fog, fatigue and bone pain, often persist despite treatment with a number of symptomatic therapies. Patients often live in fear of attacks, have limited ability to work or perform daily activities, or isolate themselves to protect against unpredictable triggers. Currently, there are no approved therapies that selectively inhibit D816V mutant KIT.
About AYVAKIT (avapritinib)
AYVAKIT (avapritinib) is a kinase inhibitor approved by the
AYVAKIT/AYVAKYT is not approved for the treatment of any other indication, including SM, in the
About Blueprint Medicines
Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have two approved precision therapies and are currently advancing multiple investigational medicines in clinical and pre-clinical development, along with a number of earlier-stage research programs. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timelines and expectations for interactions with the FDA and other regulatory authorities; plans and timelines for submitting a supplemental new drug application to the FDA for AYVAKIT for the treatment of advanced SM; expectations regarding the potential benefits of AYVAKIT in treating patients with SM; and Blueprint Medicines' strategy, goals and anticipated milestones, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the impact of the COVID-19 pandemic to Blueprint Medicines' business, operations, strategy, goals and anticipated milestones, including Blueprint Medicines' ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Blueprint Medicines' ability and plans in establishing a commercial infrastructure, and successfully launching, marketing and selling current or future approved products, including AYVAKIT and GAVRETO™ (pralsetinib); Blueprint Medicines' ability to successfully expand the approved indications for AYVAKIT and GAVRETO or obtain marketing approval for AYVAKIT and GAVRETO in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the pre-clinical and clinical results for Blueprint Medicines' drug candidates, which may not support further development of such drug candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines' ability to develop and commercialize companion diagnostic tests for its current and future drug candidates; and the success of Blueprint Medicines' current and future collaborations, partnerships or licensing arrangements, including Blueprint Medicines' global collaboration with Roche for the development and commercialization of GAVRETO. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.
1 Jennings SV, Slee VM, Zach, RM, et al. Patient Perceptions in Mast Cell Disorders. Immunol Allergy
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-data-presented-at-62nd-ash-annual-meeting-and-exposition-highlight-broad-commitment-to-advance-patient-care-in-systemic-mastocytosis-301186960.html
Andrew Law, 617-844-8205, firstname.lastname@example.org OR Investor Relations Contact, Kristin Hodous, 617-714-6674, email@example.com